Actively Recruiting
Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
Led by Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. · Updated on 2025-12-03
27
Participants Needed
2
Research Sites
175 weeks
Total Duration
On this page
Sponsors
N
Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
Lead Sponsor
G
Genelux Corporation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Oncolytic virus product named Olvi-Vec combined with Platinum plus Etoposide in patients with late phase SCLC
CONDITIONS
Official Title
Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand and voluntarily sign an informed consent form.
- Age 18 years or older, any gender.
- Confirmed diagnosis of small cell lung cancer by pathology or cytology.
- Disease progression or recurrence after prior platinum-based chemotherapy and/or immunotherapy or other recommended treatments.
- At least one measurable target lesion at baseline according to RECIST 1.1 criteria.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate bone marrow, liver, and kidney function.
You will not qualify if you...
- Diagnosis of compound small cell lung cancer or transformed small cell lung cancer.
- Presence of brain metastases with neurological symptoms; however, patients with treated and stable brain metastases for over 28 days without symptoms may enroll.
- Other primary malignant tumors except certain controlled cancers such as non-melanoma skin cancer, breast cancer in situ, cervical cancer in situ, and superficial bladder cancer.
- Clinically significant cardiovascular diseases.
- Unresolved toxicity from prior anti-tumor treatments above CTCAE grade 1, except for hair loss and peripheral neurotoxicity grade 2.
- Known HIV infection or active hepatitis B or C infection.
- Received chemotherapy, targeted therapy, radiotherapy, or biological therapy less than 4 weeks before this study; or local radiotherapy within 2 weeks.
- Major surgery or significant traumatic injury within 28 days before starting the investigational drug.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Zhejiang Provincial People's Hospital
Hangzhou, China
Actively Recruiting
2
Shanghai chest hospital
Shanghai, China
Actively Recruiting
Research Team
H
Hannah Chen
CONTACT
H
Helena zhu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here